World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
58011
World Ranking
7509
National Ranking
3920

Daniel D. Von Hoff publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Daniel D. Von Hoff sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 773 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Daniel D. Von Hoff D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel D. Von Hoff sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 102 D-Index — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 1992 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Daniel D. Von Hoff is affiliated with the Translational Genomics Research Institute in the United States. Their research primarily spans the fields of medicine and biochemistry, genetics, and molecular biology, with a strong focus on oncology and molecular biology as notable subfields.

Their work covers a range of topics, including:

  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Histone Deacetylase Inhibitors Research
  • Extracellular vesicles in disease
  • Cancer, Hypoxia, and Metabolism
  • MRI in cancer diagnosis
  • Radiomics and Machine Learning in Medical Imaging

Daniel D. Von Hoff has contributed to numerous scientific publications. Selected recent papers include:

  • BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial, 2020, Nature Medicine
  • Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions, 2020, Genome Medicine
  • Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial, 2023, Journal of Clinical Oncology
  • An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study, 2022, Gastroenterology
  • Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth, 2022, Med

Their frequent publication venues include:

  • Cancer Research
  • Journal of Clinical Oncology
  • The Oncologist
  • Frontiers in Oncology
  • Gastroenterology

Frequent co-authors of Daniel D. Von Hoff are:

  • Haiyong Han
  • Erkut Borazanci
  • Derek Cridebring
  • Gayle Jameson
  • Ajay Goel

Daniel D. Von Hoff was awarded the title of Fellow of the American Association for the Advancement of Science (AAAS) in 1992.

Best Publications

  • Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Daniel D. Von Hoff;Thomas Ervin;Francis P. Arena;E. Gabriela Chiorean

  • Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

    Paolo P. Provenzano;Carlos Cuevas;Amy E. Chang;Vikas K. Goel

  • Hypersensitivity reactions from taxol.

    R B Weiss;R C Donehower;P H Wiernik;T Ohnuma

  • Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

    Daniel D. Von Hoff;Patricia M. LoRusso;Charles M. Rudin;Josina C. Reddy

  • Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

    Manuel Hidalgo;Lillian L. Siu;John Nemunaitis;Jinee Rizzo

  • Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

    Jeffrey Hrkach;Daniel Von Hoff;Mir Mukkaram Ali;Elizaveta Andrianova

  • Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

    Andrea Wang-Gillam;Chung-Pin Li;György Bodoky;Andrew Dean

  • Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449

    Charles M. Rudin;Christine L. Hann;John Laterra;Robert L. Yauch

  • Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

    Daniel D. Von Hoff;Ramesh K. Ramanathan;Mitesh J. Borad;Daniel A. Laheru

  • Tumor-stroma interactions in pancreatic ductal adenocarcinoma

    Daruka Mahadevan;Daniel D. Von Hoff

  • Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

    Daniel D. Von Hoff;Joseph J. Stephenson;Peter Rosen;David M. Loesch

  • nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

    David Goldstein;Robert Hassan El-Maraghi;Pascal Hammel;Volker Heinemann

  • Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development

    Eric K. Rowinsky;Jolene J. Windle;Daniel D. Von Hoff

  • American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants

    Martee L. Hensley;Karen L. Hagerty;Tarun Kewalramani;Daniel M. Green

  • Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis

    Denis Drygin;Adam Siddiqui-Jain;Sean O'Brien;Michael Schwaebe

  • Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

    Patricia M. LoRusso;Charles M. Rudin;Josina C. Reddy;Raoul Tibes

  • Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer

    Clifford J. Whatcott;Caroline H. Diep;Ping Jiang;Aprill Watanabe

  • A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer

    Ian Ganly;Ian Ganly;David Kirn;Susan G. Eckhardt;Gail I. Rodriguez

  • Daunomycin-induced cardiotoxicity in children and adults: A review of 110 cases

    Daniel D. Von Hoff;Marcel Rozencweig;Maxwell Layard;Milan Slavik

  • Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

    William D Tap;Zev A Wainberg;Stephen P Anthony;Prabha N Ibrahim

Frequent Co-Authors

Gary M. Clark
Gary M. Clark The University of Texas Health Science Center at San Antonio
John D. Carpten
John D. Carpten University of Southern California
Manuel Hidalgo
Manuel Hidalgo Cornell University
David Goldstein
David Goldstein University of New South Wales
David Craig
David Craig University of Southern California
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Patricia LoRusso
Patricia LoRusso Yale University
Jeffrey R. Infante
Jeffrey R. Infante Janssen (Belgium)
Jeffrey M. Trent
Jeffrey M. Trent Translational Genomics Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in healthcare but looking for flexible or alternative pathways, there are a range of online degrees related to medicine in the USA. For aspiring nurses who want to take on advanced leadership or clinical roles, exploring the cheapest DNP programs online can be a smart way to earn a Doctor of Nursing Practice without high tuition costs.

Pharmacists are also in demand, and you can now pursue the cheapest online pharmacy school options to earn a pharmacy degree remotely, opening up new opportunities while managing expenses.

Beyond patient care, the field of health informatics is rapidly expanding. Professionals in this area bridge healthcare and technology, using data to improve patient outcomes and streamline medical services.

Many students begin their healthcare career by earning a credential in billing and coding. The average cost of medical billing and coding program is comparatively affordable, making this a good entry point for those seeking quick access to the workforce.

Best Scientists Citing Daniel D. Von Hoff

Trending Scientists

Recently Published Articles